Trials / Completed
CompletedNCT02611778
Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 712 (actual)
- Sponsor
- Bioeq GmbH · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ranibizumab |
Timeline
- Start date
- 2015-12-19
- Primary completion
- 2017-12-01
- Completion
- 2018-06-06
- First posted
- 2015-11-23
- Last updated
- 2021-09-30
- Results posted
- 2021-09-30
Locations
58 sites across 12 countries: Austria, Czechia, France, Germany, Hungary, Israel, Italy, Poland, Russia, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02611778. Inclusion in this directory is not an endorsement.